Last reviewed · How we verify
Bacterial Lysates
Bacterial lysates stimulate innate and adaptive immune responses by exposing the immune system to bacterial antigens, enhancing respiratory tract defenses and reducing infection susceptibility.
Bacterial lysates stimulate innate and adaptive immune responses by exposing the immune system to bacterial antigens, enhancing respiratory tract defenses and reducing infection susceptibility. Used for Prevention of recurrent respiratory tract infections, Recurrent sinusitis, Recurrent otitis media.
At a glance
| Generic name | Bacterial Lysates |
|---|---|
| Also known as | Fan fusu |
| Sponsor | Sanofi |
| Drug class | Immunostimulant; bacterial lysate |
| Modality | Small molecule |
| Therapeutic area | Immunology; Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Bacterial lysates are preparations containing inactivated or lysed bacteria that act as immunostimulants. They work by activating pattern recognition receptors on immune cells, promoting the production of antimicrobial peptides, immunoglobulins, and cytokines that strengthen mucosal immunity in the respiratory tract. This enhanced immune priming reduces the frequency and severity of recurrent respiratory tract infections.
Approved indications
- Prevention of recurrent respiratory tract infections
- Recurrent sinusitis
- Recurrent otitis media
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea, abdominal discomfort)
- Fever
- Headache
- Local reactions at injection site (if parenteral formulation)
Key clinical trials
- Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness (PHASE2)
- Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates. (PHASE3)
- Staphylococcus and Neisseria Tablets in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. (NA)
- Bacterial Lysates on Respiratory Tract Microecology and Evaluation of the Efficacy of Prevention and Treatment of VAP (NA)
- Experimental Phage Therapy of Bacterial Infections (NA)
- PulmonarOM (Bacterial Lysates) in Respiratory Tract Infections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |